Clonidine Patent Expiration
Clonidine is used for treating high blood pressure, chest pain, and heart failure. It was first introduced by Lavipharm Sa
Clonidine Patents
Given below is the list of patents protecting Clonidine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nexiclon Xr | US8623409 | Clonidine formulation | Sep 08, 2031 | Rosemount |
| Nexiclon Xr | US8337890 | Modified release formulations containing drug-ion exchange resin complexes | Apr 17, 2027 | Rosemount |
Clonidine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Clonidine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| The PREVENT AGITATION Trial II - Children ≤1 Year | Rigshospitalet, Denmark | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | Alcon Research | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists | Leiden University Medical Center | NA |
TERMINATED
(Jul 1, 2026)
| PHASE1 |
| Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression | University of Rochester | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study | University of Wisconsin, Madison | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE1 |
| Repurposing Low-Dose Clonidine for PTSD in Veterans | Wake Forest University Health Sciences | NA |
RECRUITING
(Mar 1, 2026)
| PHASE3 |
| ACT_for Alcohol Use Disorder and Depression | Centre hospitalier de l'Université de Montréal (CHUM) | NA |
RECRUITING
(Mar 1, 2026)
| |